Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Operations: 2015-2025

Historic Cash from Operations for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$37.1 million.

  • Spyre Therapeutics' Cash from Operations fell 26.16% to -$37.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.9 million, marking a year-over-year decrease of 7.03%. This contributed to the annual value of -$157.4 million for FY2024, which is 57.55% down from last year.
  • Per Spyre Therapeutics' latest filing, its Cash from Operations stood at -$37.1 million for Q3 2025, which was up 20.29% from -$46.6 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Cash from Operations registered a high of $2.1 million during Q2 2021, and its lowest value of -$62.2 million during Q2 2024.
  • Over the past 3 years, Spyre Therapeutics' median Cash from Operations value was -$34.6 million (recorded in 2023), while the average stood at -$34.7 million.
  • In the last 5 years, Spyre Therapeutics' Cash from Operations spiked by 110.72% in 2021 and then crashed by 1,092.94% in 2022.
  • Over the past 5 years, Spyre Therapeutics' Cash from Operations (Quarterly) stood at -$19.3 million in 2021, then grew by 5.85% to -$18.1 million in 2022, then slumped by 71.09% to -$31.0 million in 2023, then decreased by 19.86% to -$37.2 million in 2024, then dropped by 26.16% to -$37.1 million in 2025.
  • Its last three reported values are -$37.1 million in Q3 2025, -$46.6 million for Q2 2025, and -$41.0 million during Q1 2025.